Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels

BACKGROUND: Pazopanib is a tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma and soft tissue sarcoma. Despite the high inter-patient variability in pharmacokinetic exposure, pazopanib is administered at a fixed dose of 800 mg once daily (QD). Pharmacokinetic exposure is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenland, Stefanie L., Katz, Daniela, Huitema, Alwin D. R., Steeghs, Neeltje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276240/
https://www.ncbi.nlm.nih.gov/pubmed/30509247
http://dx.doi.org/10.1186/s12885-018-5043-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276240/
https://www.ncbi.nlm.nih.gov/pubmed/30509247
http://dx.doi.org/10.1186/s12885-018-5043-9

Ejemplares similares